BioSig Technologies Announces Proposed Public Offering of Common Stock.

BioSig Technologies Inc. plans to offer shares of common stock or pre-funded warrants in a public offering. The offering is being led by Clear Street and Needham & Company, and the net proceeds will be used to purchase gold bullion, for working capital, and for general corporate purposes. The timing, size, and terms of the offering remain subject to market conditions.

BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device technology company, has successfully completed a $15 million public offering of common stock. The offering, led by Clear Street and Needham & Company, involved the sale of 3,852,149 shares at a public offering price of $3.90 per share, with no pre-funded warrants included [1].

The proceeds from the offering will be primarily used to purchase gold bullion, align with the company's investment strategy. Additionally, the funds will be allocated for general corporate purposes and working capital needs. This capital raise comes at a critical juncture following BioSig's recent merger with Streamex Exchange Corporation, which has shifted the company's focus toward gold tokenization infrastructure [2].

The absence of warrants in the offering structure is a strategic move that prevents future dilution, demonstrating management's confidence in maintaining equity value. The company attracted "technology and mining thought leaders" as investors, potentially bringing valuable expertise and industry connections beyond just capital [2].

The company's CEO, Henry McPhie, stated that this funding completes their capital strategy requirements for the current growth phase, allowing management to shift focus toward "accelerated shareholder value creation" through operational execution [2].

The offering was conducted through an existing shelf registration statement, indicating the company had planned for potential capital raises. Clear Street and Needham & Company acted as joint book-running managers for the offering, which was made pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 17, 2024 [1].

BioSig Technologies, Inc. maintains a strong liquidity position with a current ratio of 2.37, ensuring it can meet its short-term obligations. The company's stock has seen significant volatility with a beta of 1.65, but analysts maintain a Strong Buy recommendation with a $10 price target [1].

References:
[1] https://www.investing.com/news/company-news/biosig-technologies-raises-15-million-in-public-offering-93CH-4196183
[2] https://www.stocktitan.net/news/BSGM/bio-sig-technologies-inc-streamex-announce-closing-of-15-million-732jr47mcjm6.html